ArticleCureus2025
Comparative Study of Hemoglobin Values Measured by Continuous Non-invasive and Whole Blood Hemoglobin Monitors for Guiding Blood Transfusion in Major Oncosurgical Procedures.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients undergoing major oncological procedures are at risk of significant perioperative blood loss, leading to increased morbidity and mortality. Transfusions of blood products are associated with complications and adverse effects. Invasive (HemoCue® Hb 301 System (HemoCue AB, Angelholm, Sweden)) and continuous non-invasive (Masimo Radical-7 SpHb® (Masimo Corporation, CA, USA)) monitoring devices have been used as real-time hemoglobin monitors to guide blood transfusion.
aimOur study aims to compare the values of both devices for guiding blood transfusion in major abdominal oncosurgical procedures.
methodsThe study was conducted over 18 months on 32 patients scheduled for elective major abdominal oncological procedures. Patients were quasi-randomized for hemoglobin measurement into two groups. Group I (HemoCue® Hb 301 System) (n=16): Invasive values were obtained at baseline and intraoperatively (every 30 minutes). Group II (Masimo Radical-7 SpHb®) (n=16): Continuous non-invasive hemoglobin monitor. Both groups were compared for the measurement of hemoglobin. IBM SPSS Statistics for Windows, Version 21 (Released 2012; IBM Corp., Armonk, New York, United States) was used for statistical analysis.
resultsThe mean hemoglobin of the Masimo Radical-7 SpHb® group and the HemoCue® Hb 301 System group during the intraoperative period was not significantly different between the two groups. The blood products transfused between the Masimo Radical-7 SpHb® and the HemoCue® Hb 301 System group were comparable (p=0.917).
conclusionPatients of the Masimo Radical-7 SpHb® (non-invasive) had comparable hemoglobin values to the HemoCue® Hb 301 System group (invasive) throughout the surgery. The units of packed red blood cells (PRBC) transfusions were comparable in both groups. The Masimo Radical-7 SpHb® group had the added benefit of being non-invasive with no biohazard exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.